NA
CRBU icon

NewEdge Advisors’s Caribou Biosciences CRBU Stock Holding History

NewEdge Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.8K Buy
10,925
+525
+5% +$901 ﹤0.01% 3183
2025
Q4 		$16.5K Hold
10,400
– – ﹤0.01% 3309
2025
Q3 		$24.2K Hold
10,400
– – ﹤0.01% 3062
2025
Q2 		$13.1K Hold
10,400
– – ﹤0.01% 3102
2025
Q1 		$9.5K Hold
10,400
– – ﹤0.01% 3120
2024
Q4 		$16.5K Sell
10,400
-2,000
-16% -$4.02K ﹤0.01% 2860
2024
Q3 		$24.3K Buy
12,400
+700
+6% +$1.43K ﹤0.01% 2663
2024
Q2 		$19.2K Buy
11,700
+3,500
+43% +$11.2K ﹤0.01% 2638
2024
Q1 		$42.1K Hold
8,200
– – ﹤0.01% 2368
2023
Q4 		$47K Buy
8,200
+1,000
+14% +$4.94K ﹤0.01% 2254
2023
Q3 		$34.4K Buy
7,200
+1,000
+16% +$6.2K ﹤0.01% 2215
2023
Q2 		$26.4K Buy
6,200
+1,100
+22% +$4.94K ﹤0.01% 2298
2023
Q1 		$27.1K Buy
5,100
+3,325
+187% +$20.7K ﹤0.01% 2233
2022
Q4 		$11 Buy
+1,775
New +$15.8K ﹤0.01% 3690

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NewEdge Advisors's CRBU Position: Q1 2026 in Review

NewEdge Advisors increased its Caribou Biosciences (CRBU) stake by 5% in Q1 2026, buying an estimated $901 and bringing the position to 10,925 shares worth $20.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3183.

NewEdge Advisors first reported a position in CRBU in Q4 2022 and has held it in 14 quarters since. The position peaked at $47K in Q4 2023. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

  • NewEdge Advisors held 10,925 shares of Caribou Biosciences worth $20.8K as of Q1 2026.
  • NewEdge Advisors bought 525 Caribou Biosciences shares in Q1 2026, an estimated $901.
  • Caribou Biosciences made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3183 holding.
  • NewEdge Advisors first reported a position in Caribou Biosciences in Q4 2022 and has held it in 14 quarters since.
  • NewEdge Advisors's Caribou Biosciences position peaked at $47K in Q4 2023.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.